![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JM Zgombick, RL Weinshank, M Macchi, LE Schechter, TA Branchek and PR Hartig
Neurogenetic Corporation, Paramus, New Jersey 07652.
RDC4 is a guanine nucleotide-binding protein-coupled receptor clone originally isolated from a canine thyroid cDNA library by Libert and colleagues [Science (Washington D. C.) 244:569-572 (1989)]. We have isolated the corresponding genomic clone for RDC4, have expressed this clone in murine LM (tk-) fibroblasts, and have determined that it encodes a serotonin 5-hydroxytryptamine1D (5-HT1D) receptor. RDC4 is an intronless gene encoding a protein of 377 amino acids, which exhibits greatest sequence identity (43%) to the 5-HT1A receptor and lower overall homology to other serotonergic and catecholaminergic receptors. Membranes prepared from murine LM (tk-) fibroblasts stably transfected with this clone were shown to bind [3H]5-HT in a saturable manner and displayed an apparently homogeneous population of high affinity (Kd = 3.6 nM, Bmax = 275 fmol/mg of protein) [3H]5-HT binding sites. High affinity [3H] 5-HT binding was unchanged using assay conditions [1 microM (+/- )-pindolol and 1 microM (R)-(+/- )-SCH 23390) to pharmacologically mask 5-HT1A, 5-HT1B, and 5-HT1C receptors. Serotonergic ligands displaced specific [3H]5-HT binding with a rank order of potency expected of a 5-HT1D receptor subtype, 5- carboxyamidotryptamine greater than 5-HT greater than yohimbine greater than 8-hydroxy-2-(di-n-propylamino)tetralin greater than ketanserin = spiperone greater than zacopride. Further, transfected cells responded to addition of 5-HT by decreasing the level of forskolin-stimulated cAMP accumulation. These data indicate that the gene RDC4 encodes a functional 5-HT1D receptor.
This article has been cited by other articles:
|
|
 |
|
  K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al. Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1265 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhattacharya, K. W. Schenck, Y.-C. Xu, L. Nisenbaum, E. Galbreath, and M. L. Cohen 5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rasmussen, D. O. Calligaro, J. F. Czachura, L. J. Dreshfield-Ahmad, D. C. Evans, S. K. Hemrick-Luecke, M. J. Kallman, W. T. Kendrick, J. D. Leander, D. L. Nelson, et al. The Novel 5-Hydroxytryptamine1A Antagonist LY426965: Effects on Nicotine Withdrawal and Interactions with Fluoxetine J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 688 - 700. [Abstract] [Full Text]
|
|
|
|
|
|
N. Adham, J. M. Zgombick, J. Bard, and T. A. Branchek Functional Characterization of the Recombinant Human 5-Hydroxytryptamine7(a) Receptor Isoform Coupled to Adenylate Cyclase Stimulation J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 508 - 514. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
